Neurocognitive state and quality of life of patients with glioblastoma in Mediterranean countries: a systematic review

Baba, Mohamed Amine; Adali, Nawal

doi:10.21037/apm-21-1900

Cited by 10 publications

(7 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such post-operative morbidity has always been considered to negatively impact on OS; although only few authors investigated the real-life impact of a new or maintained post-operative de cit 8,11 . Worsening of neurological performance may be related with the risk for a delay of access to adjuvant treatments and to a reduction of the quality of life [12][13][14] .…”

Section: Introductionmentioning

confidence: 99%

Beyond resection boundaries for glioblastoma patients: is “primum non nocere” a key factor for prognosis?

Cristofori,

Rui,

Graziano

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Maximal resection has a pivotal role in the treatment of glioblastoma, prolonging both progression free survival (PFS) and overall survival (OS). Increasingly, very few studies analyze the delicate equilibrium between maximal resection, clinical outcome and prognosis. The aim of this study is to determine the impact of neurological impairment on PFS, OS and access to adjuvant therapies. Methods this retrospective study encompassed patients operated for a GBM at Fondazione IRCCS San Gerardo dei Tintori Monza (IT), from 2015 to 2023. Histological diagnosis was performed according to 2021 WHO 2021. Patients were more than 18 years old, with pre and postoperative MRI, who underwent surgery and adjuvant treatments at our institution. Results A total of 231 patients fulfilled the criteria. Patients with improvement or complete regression of preoperative deficit had higher rate of access to adjuvant therapies (p = 0.023). Patients with hemiparesis at discharge had the worst PFS (median 4.60 months), Vs patients with aphasia, (6.60 months) Vs 9.67 for patients with normal examination (p < 0.0001). Median OS was 19.30 months for patients with hemianopia Vs 7.73 for patients with hemiparesis and 14.03 months with aphasia (p < 0.0001). Conclusion Hemianopia has no impact on patient’s prognosis, while hemiparesis and aphasia at discharge worsen both PFS and OS and prolong time-to-treatment. The “primum non nocere” principle must be the main policy: extend the resection at the cost of a minor deficit, preserve motor and language functions, encourage home cares for the most vulnerable patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Beyond resection boundaries for glioblastoma patients: is “primum non nocere” a key factor for prognosis?

Cristofori,

Rui,

Graziano

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Neuropsychiatric disorders have been linked to several other brain diseases [6], in the case of MMD, the most frequent manifestations are depression, anxiety and other cognitive disorders [5]. However, only a few case reports of onset of a psychotic disorder following a stroke have been found.…”

Section: Introductionmentioning

confidence: 99%

A psychiatric clinical picture revealing moyamoya disease

Stati¹,

Baba

Kharbach

et al. 2023

EUR J ENV PUBLIC HLT

Self Cite

View full text Add to dashboard Cite

Moyamoya disease (MMD) is a rare entity. It is a chronic cerebrovascular pathology characterized by stenosis and progressive occlusion of the termination of the carotid arteries. It is of reserved prognosis. Its diagnosis can be evoked on computerized tomography and magnetic resonance imaging (MRI) but is essentially based on arteriography. Its treatment must be early and essentially consists of revascularization surgery. We report the case of a patient admitted to the psychiatric emergency room for management of a behavioral disorder, mutism and auditory and visual hallucination, a cerebral MRI was performed urgently and the diagnosis of MMD was laid. Through this observation and a review of the literature, we discuss the characteristics of this rare condition, in particular the psychiatric comorbidity.

show abstract

“…In addition to the low five-year survival rate, the quality of the time remaining for patients is low, not restricted to the patients themselves, but affecting family members and the entire environment. Although most studies focus on prolonging life, few focus on quality of life, leading to an ethical dilemma about dysthanasia (Davis & Mulligan Stoiber, 2011;Stahl, et al, 2020;Baba & Adali, 2021). Baba and Adali (2021) cite a considerable reduction in orientation, attention, calculation speed and language fluency with the use of temozolomide and radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

“…Although most studies focus on prolonging life, few focus on quality of life, leading to an ethical dilemma about dysthanasia (Davis & Mulligan Stoiber, 2011;Stahl, et al, 2020;Baba & Adali, 2021). Baba and Adali (2021) cite a considerable reduction in orientation, attention, calculation speed and language fluency with the use of temozolomide and radiotherapy. However, there is heterogeneity and lack of specific scales to assess the quality of life in glioblastoma, making an analysis with greater methodological rigor difficult (Domenech, Hernandez & Balana, 2021).…”

Section: Introductionmentioning

confidence: 99%

Quality of life in glioblastoma after the introduction of temozolomide: a systematic review

Dias

Couto

Cardoso

2022

RSD

View full text Add to dashboard Cite

Introduction: Gliomas are primary tumors of the central nervous system with an aggressive pattern of progression with a poor prognosis in terms of survival and quality of life. The current standard treatment consists of surgery with maximum excision associated with radiotherapy and chemotherapy, based mostly on the use of temozolomide. Since its introduction, the quality of life of patients undergoing this therapy has not been widely targeted and evaluated. Objective: To verify the quality of life of patients with glioblastoma after the introduction of temozolomide in the therapeutic protocols. Methods: A systematic literature review guided by the PICO and PRISMA protocol was conducted; PubMed, Medline and Lilacs databases were consulted. Results: Initially, 77 studies were found, after selection criteria, 35 articles were analyzed. No statistically significant change was found in overall quality of life in studies that analyzed temozolomide therapy versus different control therapies. Conclusion: The association of temozolomide with surgery and radiotherapy proved to be neutral, with no significant negative or positive impacts on the quality of life of patients with glioblastoma.

show abstract

Neurocognitive state and quality of life of patients with glioblastoma in Mediterranean countries: a systematic review

Cited by 10 publications

References 78 publications

Beyond resection boundaries for glioblastoma patients: is “primum non nocere” a key factor for prognosis?

Beyond resection boundaries for glioblastoma patients: is “primum non nocere” a key factor for prognosis?

A psychiatric clinical picture revealing moyamoya disease

Quality of life in glioblastoma after the introduction of temozolomide: a systematic review

Contact Info

Product

Resources

About